Alzheimer’s Disease Studies

Pilot Clinical Studies and Development Pathway

Pilot clinical studies have been conducted across four neurological conditions to evaluate feasibility, observational outcomes, and potential directions for further clinical research.

OVERVIEW

Alzheimer’s Disease Study

Alzheimer’s disease is a progressive neurodegenerative disorder marked by declining memory, impaired attention, reduced processing speed, mood and behavioral changes, and loss of functional independence. The published studies summarized below report early clinical, electrophysiological, circulatory, and regenerative findings suggesting that biophoton therapy may support neurological function in patients with Alzheimer’s disease. Across these reports, the most consistent signals include improved EEG biomarkers, better caregiver-reported cognition, improved quality of life, better blood circulation, and no reported treatment-related adverse events in the studies summarized here.

Published Alzheimer’s Disease Study Findings

Clinical multimodal study: cognitive, EEG, vascular, and energetic changes

One published clinical study evaluated Alzheimer’s patients over 2 to 4 weeks using multiple objective tools, including quantitative EEG (qEEG), event-related potentials (ERP), vascular Doppler assessment, and additional energetic imaging methods. In the clinical cohort, 12 patients completed 4 weeks of therapy. Caregiver-reported Alzheimer’s Questionnaire scores improved significantly, with the mean score decreasing from 22.75 at baseline to 15.5 at Week 4, and 9 of 12 participants showing a clinically meaningful improvement of more than 5 points. Quality-of-life scores also improved significantly over the same 4-week period, with 10 of 12 participants showing improvement.

The same study reported qEEG changes consistent with improved cortical activation and cognitive processing. In one representative patient, the table on pages 3 to 5 shows that eyes-closed posterior peak frequency rose from 9.4 to 10.3 Hz, eyes-open posterior peak frequency rose from 8.8 to 10.5 Hz, theta/beta ratio fell from 1.16 to 0.44, frontal alpha asymmetry shifted from negative to positive, and working-memory ERP latency improved from 584 ms to 468 ms after two weeks of active treatment. By contrast, the placebo-phase example in the same paper showed no subjective symptom improvement and no clear overall therapeutic pattern.

The vascular data in the charts on page 6 showed rising peripheral blood-circulation indices in the treatment group from baseline through Week 4, while the control group remained flat or declined slightly. The same paper also described 3D non-linear brain scans showing stronger compensatory reactions and complete elimination of “nidus of defeat” markers in two illustrative dementia cases after therapy, suggesting broader physiologic changes beyond standard EEG.

Quantitative EEG study: objective evidence of cognitive restoration

A separate EEG-focused publication reported a randomized, triple-blinded, placebo-controlled clinical trial in Alzheimer’s disease, with four patients analyzed in detail using serial EEG recordings. The paper states that placebo-phase data showed negligible EEG changes, while active treatment over 2 to 4 weeks was associated with increased alpha and beta activity, reduced delta and theta slowing, improved coherence, higher EEG entropy, and better ERP markers.

In one crossover case, the placebo phase produced only minor fluctuations without meaningful neurophysiological improvement. After active treatment began, posterior alpha frequency increased, vigilance regulation improved, and ERP/behavioral metrics supported better attention and memory processing. In another patient, the table on pages 4 and 5 shows the typical pattern described by the authors: delta and theta power decreased over time, alpha and beta power increased, peak alpha shifted toward more normal values, coherence improved across long-range networks, entropy increased, and P300 responses became more robust.

In a third case, the tables on pages 5 and 6 reported reduction of delta and theta activity, increased alpha and beta power, improved frontal-parietal and interhemispheric coherence, higher signal complexity, and improved P300 amplitude and latency after just two weeks. Taken together, the EEG study suggests that active treatment was associated with measurable improvement in attention, working memory, cortical organization, and network connectivity in Alzheimer’s patients.

Functional brain age study: short-interval reversal of electrophysiological aging

A 2026 case-series paper examined EEG-derived functional brain age in five patients with mild to moderate Alzheimer’s disease during a 4-week biophoton therapy intervention. At baseline, all patients showed functional brain ages older than their chronological ages. Over the observation period, all five cases showed directional improvement, with reductions in functional brain age ranging from about 3 to 8 years over 2 to 6 weeks.

The table on pages 4 and 5 summarizes the individual trajectories: AD-128 improved by 6 functional years, AD-110 by 3 years, AD-121 by 5 years, AD-123 by 5 years, and AD-126 by 8 years. The paper attributes these changes mainly to improved posterior alpha organization and shorter ERP latencies related to attention and working memory. The headmaps shown on pages 3 and 4 also illustrate progressive normalization of spectral deviations over time in a representative case.

This study is important because it frames the EEG changes not just as isolated biomarkers, but as a composite measure of functional neural aging that can shift over short intervals. The authors conclude that functional brain age may serve as a sensitive longitudinal biomarker for future Alzheimer’s intervention studies.

Blood-fluidity and microcirculation case study

Another published case report focused on a 59-year-old woman with early-stage Alzheimer’s disease who was followed over four weeks using live blood microscopy. At baseline, the patient showed rouleaux formation, erythrocyte aggregation, oxidative-stress features, cloudy plasma, and findings interpreted as impaired blood flow and poor oxygenation. By Day 3, the study reported reduced rouleaux formation, improved cell separation, cleaner plasma, and increased oxygenation. By Day 5, the blood field was described as near-optimal, with round, well-separated red blood cells and minimal inflammatory debris. By Days 13, 18, and 27, these improvements were reportedly sustained, and the Day 27 image was described as showing peak blood quality with excellent dispersion, clear plasma, and minimal inflammatory burden.

The timeline summarized on page 5 shows a progression from abnormal aggregation and oxidative stress at baseline to reduced rouleaux by Day 3, excellent morphology by Day 5, stable clean plasma by Day 13, sustained vitality by Day 18, and peak blood quality by Day 27. The paper interprets these changes as possible support for improved microcirculation, oxygen delivery, and systemic homeostasis in early Alzheimer’s disease.

Regenerative relevance: endogenous stem-cell mobilization

Although not limited to Alzheimer’s disease, an additional randomized, double-blinded, placebo-controlled study reported that two weeks of active biophoton exposure increased circulating stem/progenitor cell populations, including a 2.7-fold increase in CD34⁺ cells, a 3.5-fold increase in CD133⁺ cells among leukocytes, and a 3.1-fold increase in CD34⁺/CD133⁺ cells. No meaningful placebo effect was observed. The same study also reported significant improvement in SF-36 quality-of-life scores and significant reduction in pain-related disability, with no adverse events reported.

These findings are not Alzheimer’s-specific, but they may help explain why some Alzheimer’s studies observed improvements in electrophysiology, circulation, and patient functioning over relatively short time periods. The study suggests that biophoton exposure may influence endogenous repair pathways relevant to neurodegenerative disease.

Safety findings relevant to Alzheimer’s disease

A broader review of biophoton quantum medicine in neurodegenerative diseases summarized clinical experience across several conditions and reported no adverse events across 318 participants in multiple studies, including a listed Alzheimer’s disease study. The safety table on page 3 reports zero adverse events in all listed studies, and the review describes the modality as non-invasive, non-thermal, and drug-free.

While this is not a dedicated Alzheimer’s efficacy trial, it supports the safety context for the Alzheimer’s studies above and is consistent with the individual Alzheimer’s papers, which also do not report treatment-related adverse events.

What these Alzheimer’s studies suggest

Taken together, the published Alzheimer’s disease studies suggest several recurring patterns:

Clinical and caregiver-reported cognition improved in many participants, including significant improvement in Alzheimer’s Questionnaire scores over four weeks in one study.

Objective neurophysiological markers improved, including posterior alpha frequency, theta/beta balance, frontal alpha asymmetry, ERP latencies, coherence, entropy, and EEG-derived functional brain age

Circulatory findings improved in both vascular assessment and live blood microscopy, suggesting better blood flow, oxygen delivery, and microvascular conditions. The circulation charts on page 6 of the multimodal paper and the live-blood sequence across pages 2 to 5 of the blood-fluidity paper both support this direction.

No adverse events were reported in the summarized studies and reviews.

Conclusion

The published Alzheimer’s disease studies report encouraging early evidence that biophoton therapy may support cognitive and neurophysiological function in patients with Alzheimer’s disease. Across multimodal clinical observation, EEG-focused reports, functional brain age analysis, and blood-fluidity assessment, the reported findings include improved caregiver-reported cognition, better quality of life, favorable EEG changes, improved circulation, and signals of enhanced endogenous repair. These findings remain preliminary and require confirmation in larger controlled trials, but they provide an initial published basis for continued investigation of non-invasive biophoton-based approaches in Alzheimer’s disease.

Disclaimer: BrainHealing.com provides informational content regarding investigational neurological treatment programs and related scientific development activities. The information presented on this website is intended for investors, researchers, healthcare professionals, and potential strategic partners.

The investigational programs described on this website are under evaluation and are not offered for commercial sale. Statements on this website should not be interpreted as claims of regulatory approval, medical efficacy, or therapeutic effectiveness unless explicitly stated.

Nothing on this website constitutes medical advice. Individuals should consult qualified healthcare professionals regarding medical conditions or treatment decisions.